Ratings Novavax, Inc.

Equities

NVAX

US6700024010

Market Closed - Nasdaq Other stock markets 03:59:48 2024-06-04 pm EDT			5-day change	1st Jan Change
17.73 ^USD	-2.69%		+14.28%	+269.38%

Jun. 03	COVID shots should target JN.1, KP.2 subvariants in 2024-25 campaign, US FDA staff says	RE
May. 28	Sanofi and Novavax Announce Co-Exclusive Licensing Agreement to Co-Commercialize Covid-19 Vaccine and Develop Novel Flu-Covid-19 Combination Vaccines	CI

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Over the past four months, analysts' average price target has been revised upwards significantly.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
NOVAVAX, INC.	+269.38%	2.56B	C-
MODERNA, INC.	+46.19%	56.65B	B-
IQVIA HOLDINGS INC.	-6.14%	39.44B	B
LONZA GROUP AG	+39.19%	39.03B	A
CELLTRION, INC.	-6.65%	26.86B	C
ICON PUBLIC LIMITED COMPANY	+12.33%	26.75B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.78%	19.03B	B
BIO-TECHNE CORPORATION	-0.35%	12.28B	B+
UNITED THERAPEUTICS CORPORATION	+24.18%	12.26B	B+
MEDPACE HOLDINGS, INC.	+28.38%	12.04B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes